Rchr
J-GLOBAL ID:201901008599742391
Update date: Jul. 12, 2024 Hidemitsu Nakajima
ナカジマ ヒデミツ | Hidemitsu Nakajima
Affiliation and department: Research field (5):
Molecular biology
, Pharmacology
, Nervous system function
, Biomedical engineering
, Biomaterials
Research keywords (15):
Animal Behavioral Sciences
, LLPS
, 多機能性タンパク質集合体 Moon Lighting Proteins-Body (MP-body)
, 創薬
, 脳神経疾患
, 脳アミロイドーシス
, 精神疾患
, タンパク質凝集
, 酸化ストレス
, 社会性ストレス
, GAPDH
, PARP
, Extracellular poly(ADP-ribose)
, Lipocalin-type prostaglandin D synthase (L-PGDS)
, Botulinum neurotoxin
Research theme for competitive and other funds (18): - 2024 - 2029 Therapeutic strategy in brain amyloidosis based on GAPDH aggregate common cross-seed hypothesis and
- 2024 - 2026 Therapeutic effects of a novel GAPDH aggregation inhibitor in multiple system atrophy
- 2022 - 2024 Exploring of a novel drug based on Liquid-Liquid Phase Separation (LLPS) in cells
- 2020 - 2023 Basic research on soybean protein and related components based on active sulfur molecules
- 2017 - 2021 Development of a new model of cat-type GAPDH knock-in Alzheimer disease by the latest genome editing method
- 2016 - 2020 Elucidation of the pathogenesis of stress-related psychiatric disorders based on the GAPDH cascade and development of treatment strategies
- 2016 - 2019 Regulation of redox signaling by reactive sulfur species in nervous system
- 2015 - 2017 A neurotrophic role of extracellular poly (ADP-ribose) in neurological sdisorders
- 2013 - 2016 Development of poorly water-soluble drug encapsulated protein nanocapsule possessing cancer directivity and application to DDS
- 2013 - 2016 A novel therapeutic target for neurological disoders by inhibition of GAPDH aggregation
- 2013 - 2014 新規ターゲット・GAPDH凝集阻害による脳神経疾患薬の創製
- 2012 - 2013 新規GAPDH凝集阻害剤によるアルツハイマー病治療薬開発の更なる展開 :ペプチドミミックによる非ペプチド性低分子化合物の創製
- 2011 - 2012 GAPDH凝集阻害剤の創製による新規アルツハイマー病治療薬の開発
- 2010 - 2012 Research for therapeutic application of dominant negative GAPDH molecule on oxidative stress-induced disorder
- 2009 - 2011 Development of intelligent-type drug delivery system by transporter protein.
- 2009 - 2011 Preclinical study for the therapeutic application of botulinum neurotoxin to intractable brain disorders.
- 2009 - 2011 Development of drug delivery system using intravital transporter protein.
- 2007 - 2008 Role of GAPDH amyloid-like fibrils formation in neurodegenerative diseases
Show all
Papers (63): -
Masanori Itakura, Takeya Kubo, Akihiro Kaneshige, Hidemitsu Nakajima. Glyceraldehyde-3-phosphate dehydrogenase regulates activation of c-Jun N-terminal kinase under oxidative stress. Biochemical and Biophysical Research Communications. 2023. 657. 1-7
- Kazuhiro Nishiyama, Kimiya Aono, Yasuyuki Fujimoto, Mitsuru Kuwamura, Toshiya Okada, Hayato Tokumoto, Takeshi Izawa, Ryoichi Okano, Hidemitsu Nakajima, Tadayoshi Takeuchi, et al. Chronic kidney disease after 5/6 nephrectomy disturbs the intestinal microbiota and alters intestinal motility. Journal of cellular physiology. 2019. 234. 5. 6667-6678
- Katsura Takano, Keisuke Koarashi, Kenji Kawabe, Masanori Itakura, Hidemitsu Nakajima, Mitsuaki Moriyama, Yoichi Nakamura. Insulin expression in cultured astrocytes and the decrease by amyloid β. Neurochemistry international. 2018. 119. 171-177
- Kazuhiro Nishiyama, Takashi Fujita, Yasuyuki Fujimoto, Hidemitsu Nakajima, Tadayoshi Takeuchi, Yasu-Taka Azuma. Fatty acid transport protein 1 enhances the macrophage inflammatory response by coupling with ceramide and c-Jun N-terminal kinase signaling. International immunopharmacology. 2018. 55. 205-215
-
Kazuhiro Nishiyama, Ai Morioka, Satomi Kita, Hidemitsu Nakajima, Takahiro Iwamoto, Yasu-Taka Azuma, Tadayoshi Takeuchi. Na+/Ca2+ Exchanger 1 Transgenic Mice Display Increased Relaxation in the Distal Colon. Pharmacology. 2018. 230-238
more... MISC (155): -
居原 秀, 赤池 孝章, 中嶋 秀満, 笠松 真吾. 活性イオウ分子を基軸とした大豆たん白質および関連成分の基礎的研究-Fundamental Research on Soy Protein and Related Components Based on Reactive Sulfur Species-第24回研究報告会記録. 大豆たん白質研究 / 不二たん白質研究振興財団 [編]. 2022. 24. 42. 1-5
-
牛飼裕美, 藤本泰之, 井澤武史, 桑村充, 中嶋秀満, 竹内正吉, 東泰孝. NASHモデルを用いたIL-19が病態形成に及ぼす影響. 日本獣医学会学術集会講演要旨集. 2019. 162nd
-
居原秀, 岸本祐典, 笠松真吾, 中嶋秀満, 赤池孝章. アルツハイマー病およびてんかんモデルマウスにおける8-nitro-cGMP産生と神経活動への影響. 日本NO学会学術集会プログラム抄録集. 2019. 19th
-
中村素直, 尾崎祐介, 東泰孝, 竹内正吉, 中嶋秀満. 社会性ストレスモデルにおけるGAPDHカスケードの病態生理学的意義の解明. 日本獣医学会学術集会講演要旨集. 2018. 161st
-
西山和宏, 東泰孝, 中嶋秀満, 西田基宏, 西田基宏, 竹内正吉. マクロファージに発現する脂肪酸輸送タンパク質の免疫学的役割. トランスポーター研究会年会抄録集. 2018. 13th
more... Patents (6): -
NON-PEPTIDIC GAPDH AGGREGATION INHIBITOR
-
Non-peptidic GAPDH aggregation inhibitor
-
GAPDH凝集阻害剤
-
ドラッグデリバリーシステムに用いる薬剤運搬体とそれを用いた医薬品および化合物の溶解補助剤とそれを含む組成物
-
三環性フタラジノン誘導体からなるポリ(ADP-リボース)合成酵素阻害剤
more... Lectures and oral presentations (14): -
新規GAPDH凝集阻害薬による脳アミロイドーシス治療薬の創製 -コモンクロスシード仮説から創薬へ-
(第8回大阪公立大学アカデミア創薬シンポジウム「産官学のギャップを埋める創薬エコシステムの構築に向けて」 2023)
-
コモンクロスシード仮説から創薬へ~新規GAPDH凝集阻害薬による広域スペクトラム脳アミロイドーシス治療薬の創製~
(第7回大阪公立大学アカデミア創薬シンポジウム「新たな作用機序による創薬を目指して」 2023)
-
多機能性酵素GAPDHのレドックス制御と脳神経疾患-GAPDHカスケードを標的とした創薬研究と治療戦略-
(大阪大学 蛋白質研究所 高次脳機能学セミナー 2023)
-
GAPDH Aggregation Inhibitor for the Treatment of Cranial Neuropathy
(2019)
-
Oxidative stress-induced GAPDH nuclear translocation in the hippocampus causes depression behaviors by GR and BDNF downregulation in stressed mice. (Best Poster Award)
(Internatinal Conference on Alzheimer’s Disease & Dementia2019 2019)
more... Professional career (1): Awards (3): - 2019/07 - International Conference on Alzheimer's Disease & Dementia Best Poster Award Oxidative stress-induced GAPDH nuclear translocation in the hippocampus causes depression behaviors by GR and BDNF downregulation in stressed mice
- 2019/05 - 大阪府獣医師会 中村賞(学術) GAPDHカスケードを基軸とした創薬研究
- 2018/02 - 創薬シーズ事業化コンペティション(大阪府) 最優秀賞 難治性脳神経疾患の革新的独自シーズ〜GAPDH凝集阻害薬〜
Association Membership(s) (7):
Japanese Veterinary Society of Animal Behavior
, 日本生化学会
, American Society for Biochemistry and. Molecular Biology: Regular Member
, 日本神経化学会
, Society for Neuroscience: Regular Member
, 日本薬理学会(評議員)
, 日本獣医学会(評議員)
Return to Previous Page